Last week, the DEA ditched plans to place five tryptamines on Schedule I after a small group of researchers, psychedelic startups and lawyers challenged the agency. Psychedelic Alpha was presented with around 200 documents pertaining to the docket, including evidence that was set to have its day in court on August 22nd. We sifted through these documents, along with public comments…


Previous articleCOMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Next articlePT342 – Spencer Hawkswell – The Right to Psilocybin in Canada: TheraPsil’s Charter Challenge